NVAX Stock Price History and Quote Analysis Insights for Investors
Novavax, Inc.
Stock Price Today
Novavax, Inc. (NVAX) stock declined over -0.72%, trading at $9.01 on NASDAQ, down from the previous close of $9.07. The stock opened at $9.10, fluctuating between $8.91 and $9.16 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Company Information
| Employees | 1543 |
| Beta | 2.09 |
| Sales or Revenue | $983.71M |
| 5Y Sales Change% | 4.264% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Novavax, Inc. (NASDAQ: NVAX) stock price is $9.01 in the last trading session. During the trading session, NVAX stock reached the peak price of $9.16 while $8.91 was the lowest point it dropped to. The percentage change in NVAX stock occurred in the recent session was -0.72% while the dollar amount for the price change in NVAX stock was -$0.07.
The NASDAQ listed NVAX is part of Biotechnology industry that operates in the broader Healthcare sector. Novavax, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Biegie Lee
Senior Vice President & Chief Information Officer
Mr. Troy Morgan Esq., J.D.
Senior Vice President & Chief Compliance Officer
Ms. Erika S. Trahan
Associate Director of Investor & PR
Mr. Stanley Charles Erck
Advisor
Mr. John A. Herrmann III
Executive Vice President, Chief Legal Officer & Corporation Sec.
Mr. Richard P. Crowley
Executive Vice President & Chief Operating Officer
Dr. Gregory M. Glenn
Pres of R&D
Dr. Gale E. Smith
Senior Vice President of Discovery & Pre-Clinical Research and Chief Scientist
Dr. Gregory M. Glenn M.D.
Pres of R&D
Mr. John A. Herrmann III, J.D.
Executive Vice President & Chief Legal Officer
Mr. John Joseph Trizzino B.S., M.B.A.
Executive Vice President, Chief Commercial Officer & Chief Bus. Officer
Dr. Filip Dubovsky FAAP, M.D., M.P.H.
Pres of R&D
Ms. Jill Hoyt SPHR
Executive Vice President & Chief HR Officer
Ms. Silvia Taylor M.B.A., MBA
Executive Vice President and Chief Corporation Affairs & Advocacy Officer
Mr. James Patrick Kelly C.F.A.
Executive Vice President, Chief Financial Officer & Treasurer
NVAX's closing price is 156.94% higher than its 52-week low of $3.53 where as its distance from 52-week high of $23.86 is -61.99%.
Number of NVAX employees currently stands at 1,543.
Official Website of NVAX is: https://www.novavax.com
NVAX could be contacted at phone 240 268 2000 and can also be accessed through its website. NVAX operates from 21 Firstfield Road, Gaithersburg, MD 20878, United States.
NVAX stock volume for the day was 343.55K shares. The average number of NVAX shares traded daily for last 3 months was 6.16M.
The market value of NVAX currently stands at $1.44B with its latest stock price at $9.01 and 160.19M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com